Company's declining EPS, below market expectations, may have...
Company's declining EPS, below market expectations, may have deterred investors. Past performance led to total loss for shareholders, raising future concerns. Dividend payouts, assumed reinvested, helped offset some losses.
Sino Biopharmaceutical (HKG:1177) Investors Are Sitting on a Loss of 62% If They Invested Three Years Ago
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment